A potential precision medicine approach for treating vision loss
Columbia University Medical Center (CUMC) and University of Iowa scientists have used a new gene-editing technology called CRISPR to repair a genetic mutation responsible for retinitis pigmentosa (RP), an inherited condition that causes the retina to degrade and leads to blindness in at least 1.5 million cases worldwide.
The study was published in Scientific Reports, and marks the first time researchers have replaced a defective gene associated with a sensory disease in stem cells that were derived from a patient’s tissue.
“Our vision is to develop a personalized approach to treating eye disease,” says Stephen Tsang, MD, PhD, the László Z. Bitó Associate Professor of Ophthalmology and associate professor of Pathology & Cell Biology at CUMC, ophthalmologist at NewYork-Presbyterian/Columbia, and one of the study’s senior authors. “We still have some way to go, but we believe that the first therapeutic use of CRISPR will be to treat an eye disease. Here we have demonstrated that the initial steps are feasible.”
In the study, the researchers created stem cells from a sample of skin that was taken from a patient with retinitis pigmentosa. As the patient-derived stem cells still harbored the disease-causing mutation, the teams used CRISPR to repair the defective gene. The stem cells can potentially be transformed into healthy retinal cells and transplanted back into the same patient to treat vision loss.
“The X-linked form of retinitis pigmentosa is an ideal candidate for a precision medicine approach because a common mutation accounts for 90% cases,” Tsang explains. Using CRISPR —which is easily adaptable to diverse sequences of DNA, and allows for fast and accurate editing —scientists can take a patient’s own cells and make pinpoint repairs specific to that individual’s genome.
Because the corrections are made in cells derived from the patient’s own tissue, doctors can re-transplant the cells with fewer fears of rejection by the immune system. Previous clinical trials have shown that generating retinal cells from embryonic stem cells and using them for transplantation is a safe and potentially effective procedure.
In this paper, the researchers targeted one of the most common variants of retinitis pigmentosa, which is caused by a single mistake in a gene called RGPR. The composition of RGPR—which contains many repeats and tight-binding nucleotide pairs—make it a difficult gene to edit. The researchers say that preliminary success with RGPR is therefore promising for treating other forms of the condition caused by mutations in other genes.
The current treatment for retinitis pigmentosa recommended by the National Institutes of Health—consuming high doses of vitamin A—slows down vision loss but does not cure the disease.
Other types of gene therapies for are currently undergoing clinical trials. Unlike CRISPR-based methods, these therapies introduce stretches of DNA that supplement some of the activity of the defective gene, but do not directly correct the original mutation. Follow-up studies have shown that any gains in vision from these gene supplementation therapies wane over time.
A CRISPR-driven precision medicine approach to treating retinitis pigmentosa may improve upon current therapies and restore a patient’s vision because CRISPR, with its pinpoint accuracy, can correct the fundamental genetic defect responsible for the disease. However, CRISPR technology has not yet been approved for use in humans.
The Latest on: Retinitis pigmentosa
[google_news title=”” keyword=”retinitis pigmentosa” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Retinitis pigmentosa
- Retinitis Pigmentosa News, Research and Latest Updateson September 26, 2023 at 5:00 pm
Keep abreast with the latest news related to Retinitis Pigmentosa there are 13 news items on Retinitis Pigmentosa that covers updates, breakthroughs and in-depth reports. We provide you with a ...
- Retinitis Pigmentosa: Genetics and Gene-Based Approaches to Therapyon September 23, 2023 at 5:00 pm
Significant advances have been made in the understanding of the genetics of retinitis pigmentosa (RP), a clinically and genetically heterogeneous group of disorders; and over 50 genes underlying ...
- Genetic Breakthrough Could Pave Way for Cure to Rare Hereditary Eye Diseaseon September 22, 2023 at 3:39 am
A groundbreaking discovery by scientists has illuminated the connection between the absence of the CERKL gene and the development of retinitis pigmentosa, a hereditary eye ailment. This revelation ...
- Study Confirms Retinal Structural Associations Between Retinitis Pigmentosa, Macular Edemaon September 21, 2023 at 7:57 am
Researchers also suggest potential new genetic associations with macular edema, which warrant further research.
- Researchers find new mechanisms that cause blindness and open the door to new treatmentson September 18, 2023 at 11:12 am
There are still many enigmas about the mechanism of action of the CERKL gene, which causes retinitis pigmentosa and other hereditary vision diseases. Now, a team from the University of Barcelona has ...
- SparingVision shares trial updates for rare eye disease gene therapieson September 15, 2023 at 10:17 am
The company is also planning to expand its Phase I/II PRODYGY lead candidate trial in retinitis pigmentosa to three more US sites.
- Retinitis Pigmentosa (Retinitis) Market Size and Regional Outlook Analysis 2023-2030on September 15, 2023 at 7:11 am
The Retinitis Pigmentosa (Retinitis) Market Insights of 2023 is an extensive and comprehensive report that provides a complete analysis of the market's size, shares, revenues, various segments ...
- Ocugen Retinitis Pigmentosa asset bolstered by new dataon September 13, 2023 at 1:55 am
- Retinitis Pigmentosa (Retinitis) Market Research Report Business Revenue, Size, Share Forecast by 2023 to 2030on September 7, 2023 at 12:49 pm
Global Retinitis Pigmentosa (Retinitis) Market Research report delves into a comprehensive analysis of the specified market, offering valuable insights into its current trends, dynamics ...
- Nanobody may lead to treatment for Retinitis Pigmentosaon September 6, 2023 at 5:00 pm
Sep. 2, 2020 — Retinitis pigmentosa is the most prevalent form of congenital blindness. Using a retinitis pigmentosa mouse model, researchers have now shown that targeted activation of genes of ...
via Bing News